|
Purpose A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naive patients with nonsmall-cell lung cancer. Patients and Methods Patients were randomly assigned to three schedules of pemetrexed 500 mg m2 plus gemcitabine 1, 250 mg m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. Results One hundred fifty-two eligible patients schedule A, n 59; schedule B, n 31, and schedule C, n 62 ; received a median of five schedule A ; , two schedule B ; , and four schedule C ; treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea 11% ; , fatigue 16% ; , and transaminase elevation 9% ; . Schedule A seemed less toxic compared with schedule C grade 3 or 4 events: 86% v 94%, respectively; P .19; grade 4 events: 39% v 48%, respectively; P .30 ; . Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% 95% CI, 20% to 45% ; , met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% 95% CI, 11% to 34% ; , did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. Conclusion Pemetrexed and gemcitabine administered as outlined for schedule A met the protocoldefined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated. J Clin Oncol 23: 5929-5937. 2005 by American Society of Clinical Oncology.
Preparation and Perfusion.--Preparation of the vessels and the method of perfusion have been described in detail 3 ; . A part of the arterial tree was isolated from its surrounding tissue and a section of the vessel prepared for perfusion by tying off all branches except the terminal one. The vessel segment was eannulated at its proximal end and mounted in a muscle chamber. The perfusion fluid, warmed 37C ; and aerated 95% O2-5% CO 2 ; physiological salt solution entered through the cannula and flowed out through the free terminal branch into the muscle chamber. A constant flow rate was maintained by a modified Sigma motor pump. Perfusion pressure was recorded by a pressure transducer, through the side arm of the cannula. Flow rate was recorded as the rate of increasing volume of outflow from the muscle chamber into an automatically emptying glass tube. Tracings from the experiments can be seen in Figure 1. Since perfusion was at constant flow rate, a rise in perfusion pressure indicates an increase in resistance vasoconstriction ; , and a fall in perfusion pressure indicates a decrease in resistance vasodilatation ; . Solutions and Drugs.--The composition of the basic perfusion fluid, physiological salt solution, in millimoles per liter, was: NaCl, 119.0; KC1, 4.7; KH, PO4, 1.18; MgSO4 7H. , O 1.17; NaHCOs, " 14.9; dextrose, 5.5; sucrose, 50.0.
Gemcitabine radiosensitization
Measurements In the conscious resting dogs, the implanted electromagnetic flow probes were connected to a Gould Statham SP 2202 flowmeter Cleveland, Ohio ; for continuous measurement of coronary or aortic flow. The external diameter of the epicardial artery was monitored by ultrasonic transit time analysis between the implanted perivascular crystals, and the arterial pressure was obtained by a Statham P23 pressure transducer from either the punctured carotid artery in the cutaneous loop or the aortic catheter. Heart rate was derived from the arterial pressure signal. Mean and phasic tracings of all variables were recorded on a Watanabe linear recorder Herrsching, FRG ; . In the dogs of group 2 under anesthesia, mean and phasic central venous and arterial pressures were recorded continuously, and the effective vascular compliance of the total vascular system23 was obtained by relating changes in central venous pressure to the changes in blood volume during a cycle of blood infusion, withdrawal, and reinfusion during 11 minutes as described previously. "1l21'22.
4. Roychowdhury DF, Cassidy CA, Peterson P et al. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002; 20: 311315. Takada M, Negoro S, Kudo S et al. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group A ; phase II study. Cancer Chemother Pharmacol 1998; 41: 217222. Zatloukal P, Kanitz E, Magyar P et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer 1998; 22: 243250. Sorensen JB, Bergman B, Nielsen AL et al. Phase II study of gemcitabine and vindesine in patients with previous untreated non-resectable non-small-cell lung cancer. Br J Cancer 1999; 79: 875881. Dimopoulou I, Efstathiou E, Samakovli A et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 2004; 15: 12501255. Chen YM, Perng RP, Yang KY et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable stage IIIB IV ; non-small cell lung cancer. Chest 2000; 117: 15831589. Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 7377. Pavlakis N, Bell DR, Millward MJ et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286291. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114: 17791781. Attar EC, Ervin T, Janicek M et al. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol 2000; 18: 697698. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000; 24: 977980. Rosado MF, Kett DH, Schein RMH et al. Severe pulmonary toxicity in a patient treated with gemcitabine. J Clin Oncol 2002; 25: 3133. Joerger M, Gunz A, Speich R et al. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002; 132: 1720. Gupta N, Ahmed I, Steinberg H et al. Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. J Clin Oncol 2002; 25: 96100. Hammerer V, Schmitz N, Pauli G et al. Interstitial lung disease in a patient treated with gemcitabine. Rev Pneumol Clin 2002; 58: 2326. Sabria-Trias J, Bonnaud F, Sioniac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir 2002; 19: 645647. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1998; 80: 286291. Marruchella A, Fiorenzano G, Merizzi A et al. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11: 504506. Dunsford ML, Mead GM, Bateman AC et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10: 943947. Girard T, Mouthon L, Boaziz C et al. Favorable outcome of gemcitabine-induced respiratory distress syndrome. Ann Med Interne Paris ; 2000; 151: 306308. De Lavigerie B, Joasson JM. Acute respiratory distress syndrome after antineoplastic chemotherapy. Probable role of gemcitabine. Presse Med 2001; 30: 851854. Mommens V, Bosquee L, D'Orio V. Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis. Rev Med Liege 2003; 58: 123126. Carron PL, Cousin L, Caps T et al. Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med 2001; 27: 1554. Vansteenkiste JF, Bomans P, Verbeken EK et al. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 2001; 31: 8385. Sauer-Heilborn A, Kath R, Schneider CP et al. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125: 637640. Maas KW, van der Lee I, Bolt K et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine cisplatin as part of combined modality treatment. Lung Cancer 2003; 41: 345351.
Gemcitabine liposome
The vacuum constriction device VCD ; works by a combination of the twin principles of vacuum and tension: the negative pressure vacuum ; device increases corporeal blood flow, thereby inducing an erection, which is maintained by a constriction ring tension ; around the base of the penis that decreases corporeal venous drainage. VCD was developed over 100 years ago. Dr. John King introduced the first device in 1874, and the first patent was issued for the device to Dr. Otto Lederer in 1917. It took over 100 years before the device was approved as a legal treatment option; Osbon`s device ErecAidTM ; was granted FDA permission in 1982 Osbon 1983 ; . It has been reported that erections have succeeded in 84-95% of cases Nadig et al. 1986, Cookson & Nadig 1993, Baltaci et al. 1995 ; and overall satisfaction with the device has been slightly lower, 72-94% Turner et al. 1991, Price et al. 1991, Vrijhof et al. 1994 ; . Complications are generally of minor nature: pain, either during the suction 20-40% ; or caused by the ring 45% ; , is the commonest complaint, which is most frequently presented at the beginning of treatment Turner et al. 1990 ; . Pain on ejaculation has been reported by 3-16% of users, and an inability to ejaculate by 12-30% Witherington 1989, Turner et al. 1991, Cookson & Nadig 1993 ; . Petechiae on the penis have been reported by 25-39%, concurrent bruising by 6-20% Cookson & Nadig 1993, Baltaci et al. 1995 ; , and numbness as a major problem during erection by 5% Cookson & Nadig 1993 ; . Few serious complications have been reported, usually due to misuse of the device, such as skin necrosis Meinhardt et al. 1990 ; , Peyronie`s disease Kim & Carson 1993 ; and Fournier`s gangrene Theiss et al. 1995 ; . Many find the main disadvantage of the VCD to be the lack of spontaneity in the production of effective erection and some men complain that the rings act as a reminder of their inadequacy Turner et al. 1992 ; . In patients who fail to respond both subjectively and objectively to either intracavernosal injection or VCD, a combination of these options should be tested Chen et al. 1995.
Gemcitabine gastric cancer
Three years with methotrexate, purinethol, and vindesine. During this clinical and hematologic remission, late myeloid elements were consistently observed in the peripheral blood, evoking the diagnosis ofCML. In 1983, she relapsed with 40% blasts in the bone marrow; blast cells were undifferentiated and had the same morphological and cytochemical characteristics see Results ; as in the first acute phase. Karyotypic analysis revealed Ph' and additional abnormalities sion first Table of blast acute 3 and crisis phase Fig 2 ; in 86% and 70% with for of the mitoses, respectively and gemifloxacin.
Chronic renal failure Patients with any of the following should be referred to the renal dietitian for individual dietary assessment and advice. 1. 2. 3. CKD stages 4 and 5 GFR 30ml min 1.73m2 ; Hyperkalaemia, Serum K + 5.5mmol l on an upward trend, not acidotic. Starting an ACE Inhibitor with serum K + 5.0mmol l Malnutrition related to uraemia BMI 20kg m2 Unintentional weight loss 5% in 3 months 5. Serum PO4 1.8mmol l 6. Patients with moderate to severe nephrotic syndrome requiring no added salt diet nutritional support. 7. Renal stones patients with calcium oxalate or uric acid stones who will benefit from dietary information, at the dietitian's discretion.
Gemcitabine avastin pancreatic
Gemcitabine and vinorelbine have different mechanisms of antitumor activity, good therapeutic indices, and nonoverlapping toxicities and gemtuzumab.
| Gemcitabine plus oxaliplatin in ovarian cancerEMERGENCY PREPAREDNESS AND PHARMACY MOBILIZATION * Katie S. Bae, Nora Flint, Chris Crank Rush-Presbyterian St. Luke's Medical Center, 1653 W Congress Parkway, Chicago, IL, 60612 katie s bae rush Objectives The primary objective of this project is to evaluate and update the existing policy and procedure regarding emergency preparedness and response specific to the Pharmacy Department. To ensure that future execution of the plan is optimized and well coordinated with the Emergency Department and local plans, a table top drill will be conducted specific to the Pharmacy Department. Measures will be taken to ensure that an appropriate cache of pharmaceuticals are in stock and any additional needs will be readily retrievable. In order to ensure the advancement of ASHP 2015 initiative objective 6.5, appropriate documentation and subsequent publications will allow for increased awareness of the importance of instituting an emergency preparedness plan. Methods Existing Pharmacy Departmental plans will be examined and expanded as seen fit. This will be in coordination with the hospital wide plan for preparedness as well as local and federal plans. An organizational command plan will be included as part of the policies and procedures. An organizational plan specific to Rush will designate the appropriate chain of response during a disaster event. An emergency response team and specific roles will be identified. Since Rush is a housing site for the Chempack, it is imperative that the pharmacy department be adequately trained on the activation plan. In the hopes that our experience in implementing an emergency preparedness plans will be adaptable to other institutions, the results generated will documented for publishing and presentation purposes. Results Thus far, a "train the trainer" certificate was obtained from the Chicago Department of Public Health regarding the Chempack. This allowed for an inservice to be conducted, educating the Pharmacy Department on the components as well as the notification and activation of the Chempack. Development of an emergency preparedness resource center has yet to be completed. A table top drill is scheduled to be conducted this spring. Learning Objectives: Understand the specific role of the pharmacist in emergency preparedness. Understand the components of the Chempack in addition to the notification and activation process involved. Self Assessment Questions: The Chempack is a subset of the Strategic National Stockpile and is monitored around the clock solely by the local department of public health. True or False The Chempack contains atropine, pralidoxime, and diazepam. True or False.
Contractor is required to store medications it administers including returning unused portions to the parents at the end of the day and gemzar.
Gemcitabine review
Selenoprotein p, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
|
Developed a breakthrough Molecular FingerPrintingTM blood test for the early-detection and optimized treatment of a variety of cancers and other immune diseases. Based on monitoring diseasespecific molecular changes in gene regulatory machinery and genotropin.
1 West German Cancer Center, University of Essen; 2Department of Gastroenterology and Internal Medicine, Marienhospital Herne, University of Bochum; 3Bayer HealthCare AG, Clinical Pharmacology, Wuppertal; 4Bayer Pharmaceuticals Corporation, West Haven, CT, USA; 5M.A.R.C.O. Institute for Clinical Research and Statistics Dr. Wargenau, Du sseldorf; 6Department of Hematology and Medical Oncology, Marienhospital Herne, University of Bochum, Germany.
Parkgate Hall 6-9 Conyngham Road, Dublin 8 01 - 703 6100 Tel 01 - 703 6165 Fax Target group Homeless people aged over 18 years who are motivated to move out of homelessness. Area served Dublin City Council area. Service offered Provides pre and post settlement support to homeless rough sleepers, families in B&B accommodation and people in hostels, who are motivated to move out of homelessness. Services include assessment of housing need, keyworking, referral to housing providers, advocacy, information and help with linking into other appropriate services. How to contact Phone or contact for an appointment. Opening hours Mon 9am - 5pm Tue 9am - 5pm Wed 9am - 5pm Thu 9am - 5pm Fri 9am - 5pm Weekend Disabled access Full wheelchair access. Adapted toilets. Lift in the building. Public transport Buses: 25, 25a, 26, Type of organisation Statutory Service Staffing 12 full time staff and gentamicin.
Quality assurance Each measurement day a blank filter and a blank handwash sample were collected and analyzed together with the rest of the samples. None of these blank samples appeared to have detectable levels of any of the eight antineoplastic drugs. A 10, 100, 1000 ng series for the eight antineoplastic drugs was spiked in triplicate on the sampling materials. Average recovery efficiencies for the sampling materials are presented in Figure 3.2. The average recovery efficiencies for the handwash solution 10% isopropanol ; were good 100% ; for all eight antineoplastic drugs Figure 3.2 ; . The average recovery efficiencies for the glassfibre filters were reasonably good for seven antineoplastic drugs, but not for cytarabine 66% 6% ; Figure 3.2 ; . For the nitrile rubber gloves the average recovery efficiencies were high for gemcitabine 117% 9% ; , methotrexate 106% 8% ; , and chlorambucil 100% 10% ; , moderate for etoposide 80% 10% ; , ifosfamide 73% 5% ; , and cyclophosphamide 70% 5% ; , and poor for 5-fluorouracil 49% 8% ; and cytarabine 16% 2% ; Figure 3.2 ; . The average recovery efficiencies for the 10 x 10 sections of cotton bed sheet were good for cyclophosphamide 106% 6% ; , ifosfamide 102% 5% ; , methotrexate 112% 5.
Gemcitabine formula
The EZ REIMBURSE Card is a stored-value card. It is a convenient Medical Expense FSA reimbursement option which allows FBMC to electronically approve some eligible expenses under your employer's plan and IRS guidelines. Your annual Medical Expense FSA contribution is available to you at the beginning of your plan year. When you use your EZ REIMBURSE Card to pay for eligible expenses, funds are electronically deducted from your Medical Expense FSA and gentian.
1. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-75. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-10. Heinemann V, Quietzsch D, Gieseler F et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Soc Clin Oncol 2003; 22: 250. Abstract 1003. 6. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-16. Richards DA, Kindler HL, Oettle H et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004; 22 14S ; . Abstract 4007. 8. O'Reilly EM, Abou-Alfa GK, Letourneau R et al. A randomized phase III trial of DX-8951f exatecan mesylate; DX ; and gemcitabine GEM ; vs. gemcitabine alone in advanced pancreatic cancer APC ; . J Clin Oncol 2004; 22 14S ; . Abstract 4006. 9. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-38. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-67 and gemcitabine.
Gemcitabine pills
For example, a comparison of gemcitabine at 1, 000 mg m 2 on days 1, 8, and 15 every 28 days or 1, 000 mg m 2 on days 1 and 18 every 21 days plus cisplatin at 70 mg m 2 on day 2 with both gemcitabine regimens showed that treatment with the 21- day schedule was associated with an increase in dose intensity of both drugs due to improved delivery ; , a reduction in neutropenia 25% vs 35% ; , a reduction in thrombocytopenia 7% vs 40% ; , an increase in anemia 10% vs 0%, due to more frequent dosing of cisplatin ; , reduced nonhematologic toxicity 25% vs 33% ; , and a numeric but nonsignificant improvement in response rate 55% vs 40 and ginger.
Gemcitabine may interfere with the normal menstrual cycle in women and may stop sperm production in men.
Gemcitabine liver cancer
Calcium 45, bariatric medical equipment, amitriptyline narcotic, polymyalgia prednisone and calcium levels too high. Continuous passive motion machine video, circumcision stories, fibromyalgia doctors and henna wholesale or fibroid removal options.
Gemcitabine solubility
Gemcihabine, gemcigabine, gemcitabune, gemciyabine, gemcittabine, yemcitabine, gecitabine, gemcitablne, gemciitabine, gemcitabin4, gemcitanine, temcitabine, gemcitqbine, gemictabine, gemcitab9ne, gemvitabine, gemctabine, gdmcitabine, grmcitabine, gmecitabine.
Gemcitabine hydrochloride
Gemcitabine radiosensitization, gemcitabine liposome, gemcitabine gastric cancer, gemcitabine avastin pancreatic and gemcitabine plus oxaliplatin in ovarian cancer. Gemcitabine review, gemcitabine formula, gemcitabine pills and gemcitabine liver cancer or gemcitabine solubility.
|
